Deletion at fragile sites is a common and early event in Barrett's esophagus

Molecular Cancer Research

Volumn 8, Issue 8, 2010, Pages 1084-1094

  Lai, Lisa A ^a   Kostadinov, Rumen ^c   Barrett, Michael T ^d   Peiffer, Daniel A ^e   Pokholok, Dimitry ^e   Odze, Robert ^f   Sanchez, Carissa A ^b   Maley, Carlo C ^c   Reid, Brian J ^a,b   Gunderson, Kevin L ^e   Rabinovitch, Peter S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c WISTAR INSTITUTE   (United States)

^d TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^e ILLUMINA INC   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER RISK; CHROMOSOME FRAGILE SITE; CHROMOSOME REARRANGEMENT; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; DISEASE ASSOCIATION; DISEASE COURSE; DNA STRAND BREAKAGE; FEMALE; GENE DELETION; GENOMIC INSTABILITY; HETEROZYGOSITY; HUMAN; HUMAN CELL; MALE; MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PYROSEQUENCING; QUANTITATIVE ANALYSIS;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CHROMOSOME FRAGILE SITES; CHROMOSOME FRAGILITY; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 9; COMPARATIVE GENOMIC HYBRIDIZATION; ESOPHAGEAL NEOPLASMS; GENE DOSAGE; GENE EXPRESSION PROFILING; GENOMIC INSTABILITY; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LOSS OF HETEROZYGOSITY; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 77955764987     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-09-0529     Document Type: Article

References (51)

1. Jenkins GJ, Doak SH, Parry JM, et al. Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma. Br J Surg 2002;89:824-37.
2. Sihvo EI, Salminen JT, Rantanen TK, et al. Oxidative stress has a role in malignant transformation in Barrett's oesophagus. Int J Cancer 2002;102:551-5.
3. Wild CP, Hardie LJ. Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. Nat Rev Cancer 2003;3:676-84.
4. Morales TG, Sampliner RE. Barrett's esophagus: update on screening, surveillance, and treatment. Arch Intern Med 1999;159:1411-6.
5. Nietert PJ, Silverstein MD, Mokhashi MS, et al. Cost-effectiveness of screening a population with chronic gastroesophageal reflux. Gastrointest Endoscopy 2003;57:311-8.
6. Finley JC, Reid BJ, Odze RD, et al. Chromosomal instability in Barrett's esophagus is related to telomere shortening. Cancer Epidemiol Biomarkers Prev 2006;15:1451-7.
7. O'Sullivan JN, Finley JC, Risques RA, et al. Telomere length assessment in tissue sections by quantitative FISH: image analysis algorithms. Cytometry 2004;58A:120-31.
8. Lai LA, Paulson TG, Li X, et al. Increasing genomic instability during premalignant neoplastic progression revealed through high resolution array-CGH. Genes Chromosomes Cancer 2007;46:532-42. (Pubitemid 46649568)
9. Michael D, Beer DG, Wilke CW, et al. Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas. Oncogene 1997;15:1653-9. (Pubitemid 27466704)
10. Fang JM, Arlt MF, Burgess AC, et al. Translocation breakpoints in FHIT and FRA3B in both homologs of chromosome 3 in an esophageal adenocarcinoma. Genes Chromosomes Cancer 2001;30:292-8.
11. Yunis JJ, Soreng AL. Constitutive fragile sites and cancer. Science 1984;226:1199-204.
12. Sutherland GR, Richards RI. The molecular basis of fragile sites in human chromosomes. Curr Opin Genet Dev 1995;5:323-7.
13. Wang YH. Chromatin structure of human chromosomal fragile sites. Cancer Lett 2006;232:70-8.
14. Schwartz M, Zlotorynski E, Kerem B. The molecular basis of common and rare fragile sites. Cancer Lett 2006;232:13-26. (Pubitemid 43054977)
15. O'Keefe LV, Richards RI. Common chromosomal fragile sites and cancer: focus on FRA16D. Cancer Lett 2006;232:37-47.
16. Arlt MF, Miller DE, Beer DG, et al. Molecular characterization of FRAXB and comparative common fragile site instability in cancer cells. Genes Chromosomes Cancer 2002;33:82-92.
17. Ahmadian M, Wistuba II, Fong KM, et al. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. Cancer Res 1997;57:3664-8. (Pubitemid 27381204)
18. Fong KM, Biesterveld EJ, Virmani A, et al. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res 1997;57:2256-67. (Pubitemid 27247047)
19. Nymark P, Wikman H, Ruosaari S, et al. Identification of specific gene copy number changes in asbestos-related lung cancer. Cancer Res 2006;66:5737-43. (Pubitemid 43927127)
20. Kuroki T, Tajima Y, Furui J, et al. Common fragile genes and digestive tract cancers. Surg Today 2006;36:1-5. (Pubitemid 43015846)
21. Smith DI, Zhu Y, McAvoy S, et al. Common fragile sites, extremely large genes, neural development and cancer. Cancer Lett 2006;232: 48-57. (Pubitemid 43053933)
22. Hellman A, Zlotorynski E, Scherer SW, et al. A role for common fragile site induction in amplification of human oncogenes. Cancer Cell 2002;1:89-97. (Pubitemid 41039179)
23. Miller CT, Lin L, Casper AM, et al. Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene 2006;25:409-18. (Pubitemid 43117626)
24. Ciullo M, Debily MA, Rozier L, et al. Initiation of the breakage-fusion-bridge mechanism through common fragile site activation in human breast cancer cells: the model of PIP gene duplication from a break at FRA7I. Hum Mol Genet 2002;11:2887-94.
25. Feagins LA, Zhang HY, Hormi-Carver K, et al. Acid has antiproliferative effects in nonneoplastic Barrett's epithelial cells. Am J Gastroenterol 2007;102:10-20. (Pubitemid 46072037)
26. Zhang HY, Zhang X, Hormi-Carver K, et al. In non-neoplastic Barrett's epithelial cells, acid exerts early antiproliferative effects through activation of the Chk2 pathway. Cancer Res 2007;67:8580-7.
27. Hong MK, Laskin WB, Herman BE, et al. Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus. Cancer 1995;75:423-9.
28. Reid BJ, Sanchez CA, Blount PL, et al. Barrett's Esophagus - Cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology 1993;105:119-29.
29. Reid BJ, Blount PL, Rubin CE, et al. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 1992;102: 1212-9.
30. Galipeau PC, Li XH, Blount PL, et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. Plos Med 2007;4:342-54.
31. Paulson TG, Galipeau PC, Reid BJ. Loss of heterozygosity analysis using whole genome amplification, cell sorting, and fluorescence-based PCR. Genome Res 1999;9:482-91.
32. Palanca-Wessels MC, Barrett MT, Galipeau PC, et al. Genetic analysis of long-term Barrett's esophagus epithelial cultures exhibiting cytogenetic and ploidy abnormalities. Gastroenterology 1998;114:295-304.
33. Palanca-Wessels MC, Klingelhutz A, Reid BJ, et al. Extended life-span of Barrett's esophagus epithelium transduced with the human telomerase catalytic subunit: a useful in vitro model. Carcinogenesis 2003;24:1183-90. (Pubitemid 36927058)
34. Peiffer DA, Le JM, Steemers FJ, et al. High-resolution genomic profiling of chromosomal aberrations using Infinium whole-genome genotyping. Genome Res 2006;16:1136-48.
35. Wang P, Kim Y, Pollack J, et al. A method for calling gains and losses in array CGH data. Biostatistics 2005;6:45-58. (Pubitemid 41240369)
36. Diskin SJ, Eck T, Greshock J, et al. STAC: a method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments. Genome Res 2006;16:1149-58. (Pubitemid 44320402)
37. Boehm D, Herold S, Kuechler A, et al. Rapid detection of subtelomeric deletion/duplication by novel real-time quantitative PCR using SYBR-green dye. Hum Mutat 2004;23:368-78. (Pubitemid 38461518)
38. Feagins LA, Zhang HY, Quinones M, et al. Acid exerts an anti-proliferative effect in non-neoplastic Barrett's epithelial cells by delaying cell cycle progression. Gastroenterology 2006;130:A77.
39. Mrasek K, Schoder C, Teichmann AC, et al. Global screening and extended nomenclature for 230 aphidicolin-inducible fragile sites, including 61 yet unreported ones. Int J Oncol 2010;36:929-40.
40. Lisitsyn NA, Lisitsina NM, Dalbagni G, et al. Comparative genomic analysis of tumors: detection of DNA losses and amplification. Proc Natl Acad Sci U S A 1995;92:151-5.
41. Kameoka Y, Tagawa H, Tsuzuki S, et al. Contig array CGH at 3p14.2 points to the FRA3B/FHIT common fragile region as the target gene in diffuse large B-cell lymphoma. Oncogene 2004;23:9148-54. (Pubitemid 40013083)
42. Huebner K, Garrison PN, Barnes LD, et al. The role of the FHIT/ FRA3B locus in cancer. Annu Rev Genet 1998;32:7-31. (Pubitemid 29045306)
43. Jenkins GJ, D'Souza FR, Suzen HS, et al. Deoxycholic acid (DCA) at neutral and acid pH, is genotoxic to oesophageal cells through the induction of ROS: the potential role of antioxidants in Barrett's oesophagus. Carcinogenesis 2007;28:136-42.
44. Payne CM, Weber C, Crowley-Skillicorn C, et al. Deoxycholate induces mitochondrial oxidative stress and activates NF-{κ}B through multiple mechanisms in HCT-116 colon epithelial cells. Carcinogenesis 2007;28:215-22. (Pubitemid 44942646)
45. Glover TW, Arlt MF, Casper AM, et al. Mechanisms of common fragile site instability. Hum Mol Genet 2005;14:R197-205.
46. Durkin SG, Ragland RL, Arlt MF, et al. Replication stress induces tumor-like microdeletions in FHIT/FRA3B. Proc Natl Acad Sci U S A 2008;105:246-51.
47. Vaughan TL, Dong LM, Blount PL, et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol 2005;6:945-52.
48. Lao-Sirieix P, Roy A, Worrall C, et al. Effect of add suppression on molecular predictors for esophageal cancer. Cancer Epidemiol Biomarkers Prev 2006;15:288-93. (Pubitemid 43342176)
49. Galipeau PC, Prevo LJ, Sanchez CA, et al. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. J Natl Cancer Inst 1999; 91:2087-95.
50. Gonzalez MV, Artimez ML, Rodrigo L, et al. Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma. J Clin Pathol 1997;50:212-7. (Pubitemid 27122799)
51. Koppert LB, Wijnhoven BP, van Dekken H, et al. The molecular biology of esophageal adenocarcinoma. J Surg Oncol 2005;92: 169-90.